BR112013032224A2 - métod de administrar parenteralmente uma composição, composição farmacêutica, método de administração parenteral, uso de um fosfolipídeo krill - Google Patents

métod de administrar parenteralmente uma composição, composição farmacêutica, método de administração parenteral, uso de um fosfolipídeo krill

Info

Publication number
BR112013032224A2
BR112013032224A2 BR112013032224A BR112013032224A BR112013032224A2 BR 112013032224 A2 BR112013032224 A2 BR 112013032224A2 BR 112013032224 A BR112013032224 A BR 112013032224A BR 112013032224 A BR112013032224 A BR 112013032224A BR 112013032224 A2 BR112013032224 A2 BR 112013032224A2
Authority
BR
Brazil
Prior art keywords
composition
parenteral administration
pharmaceutical composition
parenterally administering
krill phospholipid
Prior art date
Application number
BR112013032224A
Other languages
English (en)
Other versions
BR112013032224B1 (pt
Inventor
David F Driscoll
Original Assignee
Stable Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/161,101 external-priority patent/US8895074B2/en
Application filed by Stable Solutions Llc filed Critical Stable Solutions Llc
Publication of BR112013032224A2 publication Critical patent/BR112013032224A2/pt
Publication of BR112013032224B1 publication Critical patent/BR112013032224B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract not avaible
BR112013032224-1A 2011-06-15 2012-06-13 Composição farmacêutica aplicável parenteralmente BR112013032224B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/161,101 2011-06-15
US13/161,101 US8895074B2 (en) 2011-06-15 2011-06-15 Therapeutic application of parenteral krill oil
EP11179821.1 2011-09-02
EP11179821 2011-09-02
PCT/IB2012/001156 WO2012172411A1 (en) 2011-06-15 2012-06-13 Therapeutic application of parenteral krill oil

Publications (2)

Publication Number Publication Date
BR112013032224A2 true BR112013032224A2 (pt) 2016-12-20
BR112013032224B1 BR112013032224B1 (pt) 2021-10-13

Family

ID=46456944

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032224-1A BR112013032224B1 (pt) 2011-06-15 2012-06-13 Composição farmacêutica aplicável parenteralmente

Country Status (21)

Country Link
EP (1) EP2720701B1 (pt)
JP (1) JP5864735B2 (pt)
KR (1) KR101841588B1 (pt)
CN (2) CN107648268B (pt)
BR (1) BR112013032224B1 (pt)
CA (1) CA2838312C (pt)
CY (1) CY1119417T1 (pt)
DK (1) DK2720701T3 (pt)
ES (1) ES2643843T3 (pt)
HR (1) HRP20171431T1 (pt)
HU (1) HUE036720T2 (pt)
IL (1) IL229690A (pt)
LT (1) LT2720701T (pt)
MX (1) MX351895B (pt)
PL (1) PL2720701T3 (pt)
PT (1) PT2720701T (pt)
RS (1) RS56394B1 (pt)
RU (1) RU2625760C2 (pt)
SI (1) SI2720701T1 (pt)
TW (1) TWI592160B (pt)
WO (1) WO2012172411A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014262450A1 (en) 2013-05-10 2015-12-03 Memorial Sloan Kettering Cancer Center Lipid scavenging in Ras cancers
GB201402457D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
PL3137070T3 (pl) * 2014-04-30 2020-07-13 Aker Biomarine Antarctic As Preparaty z oleju z kryla i ich zastosowania
EP3232798A1 (en) 2014-12-19 2017-10-25 Aker Biomarine Antarctic AS Enhanced omega-3 formulations
CN107567331A (zh) * 2015-03-31 2018-01-09 费森尤斯卡比德国有限公司 用于肠胃外给药的乳液
CN105901740A (zh) * 2016-04-26 2016-08-31 济南极源生物科技有限公司 一种南极磷虾油可食用营养品
SG11202000592WA (en) * 2017-08-10 2020-02-27 Childrens Medical Ct Corp Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids
EP3536332A1 (en) * 2018-03-07 2019-09-11 Athenion AG Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
KR102451162B1 (ko) * 2020-09-07 2022-10-06 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH08231391A (ja) * 1995-02-24 1996-09-10 Kanagawa Kagaku Kenkyusho:Kk 痴呆症状改善薬
DE69842121D1 (de) * 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
CN1516592A (zh) * 2001-06-18 2004-07-28 �����Ǽ���&������Դ���޹�˾ 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
US7666447B2 (en) * 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
CN101321477A (zh) * 2005-10-07 2008-12-10 加拿大海洋营养食品有限公司 脂肪酸盐及其制备和使用方法
MX292557B (es) * 2006-11-16 2011-11-24 Pronova Biopharma Norge As Proceso para la produccion de fosfolipidos marinos ricos en omega-3 a partir de krill.
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
JP5443979B2 (ja) * 2007-05-11 2014-03-19 備前化成株式会社 新規のロイコトリエン受容体アンタゴニスト
NO327925B1 (no) * 2007-06-25 2009-10-19 Pharmalogica As Anvendelse av kullsyre i drikker omfattende polyumettede fettsyrer (PUFA) for a hindre oksidasjon av fettsyrene.
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100130619A1 (en) * 2008-11-24 2010-05-27 Joseph Schwarz Pharmaceutical composition for parenteral administration of idebenone
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
NO333013B1 (no) * 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
US8609157B2 (en) * 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils

Also Published As

Publication number Publication date
CN107648268A (zh) 2018-02-02
KR20140053957A (ko) 2014-05-08
PL2720701T3 (pl) 2018-01-31
TW201302209A (zh) 2013-01-16
EP2720701A1 (en) 2014-04-23
RU2625760C2 (ru) 2017-07-18
IL229690A0 (en) 2014-01-30
CN107648268B (zh) 2021-06-22
ES2643843T3 (es) 2017-11-24
TWI592160B (zh) 2017-07-21
RS56394B1 (sr) 2017-12-29
BR112013032224B1 (pt) 2021-10-13
MX2013014901A (es) 2014-07-09
DK2720701T3 (en) 2017-10-30
CY1119417T1 (el) 2018-03-07
EP2720701B1 (en) 2017-08-09
CA2838312A1 (en) 2012-12-20
CA2838312C (en) 2019-01-08
CN103608023A (zh) 2014-02-26
IL229690A (en) 2017-01-31
RU2014101067A (ru) 2015-07-20
KR101841588B1 (ko) 2018-03-26
PT2720701T (pt) 2017-10-23
HUE036720T2 (hu) 2018-07-30
LT2720701T (lt) 2017-11-10
SI2720701T1 (sl) 2017-12-29
HRP20171431T1 (hr) 2017-12-15
JP2014517028A (ja) 2014-07-17
WO2012172411A1 (en) 2012-12-20
MX351895B (es) 2017-11-01
JP5864735B2 (ja) 2016-02-17

Similar Documents

Publication Publication Date Title
BR112013032224A2 (pt) métod de administrar parenteralmente uma composição, composição farmacêutica, método de administração parenteral, uso de um fosfolipídeo krill
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
ECSP13013074A (es) Nuevos derivados de piridina
NI201400032A (es) Piridopirazinas anticancerígenas via la
CU20160006A7 (es) Derivados de piperidinil-indol como inhibidores de factor de complemento b
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
BR112015004499A2 (pt) métodos de administração de terapia de pirfenidona
CR20150250A (es) Nuevos derivados de piridina
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
IN2015DN00185A (pt)
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
CR20150204A (es) Nuevos derivados de piridina
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
PE20151079A1 (es) Tratamiento para artritis reumatoide
CO7151499A2 (es) Formulación inyectable
BR112013025866A2 (pt) formulações com viscosidade reduzida
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
BR112015025814A2 (pt) composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
BR112013033861A2 (pt) composto, uso de um composto, composição farmacêutica, composição cosmética e uso cosmético de uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.